The evidence in support of the concepts of PrCh and of anticoagulation in the management of primary CRCa are briefly presented. The first study incorporating both these novel approaches to the treatment of CRCa with a minimum follow-up of 5 years is herein presented. Whereas no discernible differences on survival were documented on a long-term basis, when patient who ultimately recurred in each group were compared, a substantial and statistically significant prolongation of the free-of-disease interval from surgery to recurrence and of survival from recurrence to death are revealed. PRCa and anticoagulation appear to deserve further study, in the management of operable CRCa.